24/7 Customer Support
The Asia Pacific stem cell therapy market is poised for substantial growth in the coming years, with a projected compound annual growth rate (CAGR) of 10.29% between 2023 and 2031. This growth is expected to drive the market value up to US$ 3,420.05 Mn by 2031, following a successful revenue performance of US$ 1,453.61 Mn in 2022.
Several factors are driving the growth of the Asia Pacific stem cell therapy market, including the increasing demand for new and innovative medical treatments, the growing awareness of the benefits of stem cell therapy, the presence of advanced medical infrastructure and technology, and a large and aging population in the region. The rise in chronic diseases such as diabetes, cardiovascular diseases, and Alzheimer's disease is also contributing to the increasing demand for stem cell therapy treatments.
Despite this impressive growth, the Asia Pacific stem cell therapy market faces some challenges, including the lack of regulation and standardization, the high cost of treatments, and concerns about the safety and efficacy of stem cell treatments. However, with the increasing investment in research and development, and the growing body of evidence on the benefits of stem cell therapy, these challenges are likely to be addressed in the coming years.
Top 3 Drivers
1. Robust Funding for Stem Cell Research: Governments, private institutions, and investors have all committed to supporting stem cell research financially and through legal measures. This has enabled researchers to develop more effective and efficient treatments, which has led to greater demand for stem cell therapy.
2. Increasing Number of Cell Therapy Production Facilities: The increasing presence of companies in the stem cell therapy market has resulted in increased production capacity and availability of stem cell therapy, making it more affordable and appealing to potential consumers.
3. Growing Demand for Stem Cells for Medical Purposes: Stem cells can be used to treat a variety of medical conditions, such as cancer, autoimmune diseases, and blood disorders. As these conditions become more prevalent, the demand for stem cell therapies is likely to increase.
Ethical Concerns Related to Embryonic Stem Cells
Embryonic stem cell research is a complex and highly charged topic that has raised a wide range of ethical concerns in recent years. The use of embryonic stem cells in research and therapy has sparked intense debate, both in the scientific community and among members of the public. On one hand, these cells hold great promise for providing treatments for currently incurable diseases and disorders. On the other hand, many people argue that their use is unethical because it involves the destruction of human embryos.
Therapy Type Analysis
The Asia Pacific stem cell therapy market is segmented into two types: autologous and allogeneic stem cell therapy. In 2022, the allogeneic stem cell therapy segment dominates the market, holding a market share of $839.17 million. The segment's growth can be attributed to factors such as the rise of stem cell banking and fewer complications. Additionally, there has been an increase in the number of cell therapy companies that are focusing their efforts on the development of allogeneic stem cell therapies.
The Asia Pacific stem cell therapy market is divided into four categories based on product: Adult Stem Cells (ASCs), Human Embryonic Stem Cells (HESCs), Induced Pluripotent Stem Cells (iPSCs), and Very Small Embryonic Like Stem Cells. In 2022, the Adult Stem Cells (ASCs) segment dominated the market with roughly 80% market share. This segment is also projected to experience the highest compound annual growth rate of 10.53% during the forecast period.
Cell Source Analysis
The Asia Pacific stem cell therapy market is segmented into four categories based on cell source: adipose tissue-derived MSCs, bone marrow derived MSCs, placental/umbilical cord derived MSCs, and others. In 2022, the adipose tissue-derived MSCs segment held the largest share of 49% and is projected to grow at a compound annual growth rate of 10.74% during the forecast period. The demand for adipose tissue-derived MSCs is increasing due to its growing adoption for various therapeutic indications.
The Asia Pacific stem cell therapy market is segmented into four categories based on technology: cell acquisition, cell production, cryopreservation and expansion, and sub-culture. In 2022, the cell acquisition segment dominated the market with a 35% revenue share and is also projected to experience the highest compound annual growth rate of 10.73% during the forecast period. Within the cell acquisition segment, the bone marrow harvest segment holds the largest revenue share due to factors such as rising awareness, an increase in blood cancer prevalence, and easier access to therapy.
On the basis of application, the Asia Pacific stem cell therapy market is segmented into musculoskeletal disorders, Wounds and Injuries, Acute Graft-Versus-Host Disease (AGVHD), Surgeries, Gastrointestinal Diseases, Cardiovascular Diseases, Inflammatory & Autoimmune Diseases, Neurological Disorders and others. Cardiovascular diseases are expected to hold a high revenue share over the forecast period. As stem cell therapy reduced mortality, it is expected that it will be used more frequently to treat cardiovascular illnesses.
End User Analysis
In terms of end user, the Asia Pacific stem cell therapy market is segmented into hospitals, research institutes, surgical institutes and others. The hospitals segment is contributing a significant share to the market revenue due to the institute's use of tools and kits to conduct thorough research. Moreover, others segment has been estimated to grow with the highest CAGR during the forecast year, which includes pharmaceutical and biotechnology companies.
Anterogen Co. Ltd., Astellas Pharma Inc, Brainstorm Cell Limited, Fujifilm Holding Corporation and MEDIPOST Co. Ltd held over 30% of the revenue share of the Asia Pacific stem cell therapy market.
List of Key Companies Profiled:
The Asia Pacific stem cell therapy market is segmented based on therapy type, product, cell source, technology, application and end user.
By Therapy Type segmented, the Asia Pacific stem cell therapy market is sub-segmented into:
By Product segment, the Asia Pacific stem cell therapy market is sub-segmented into:
By Cell source segment, the Asia Pacific stem cell therapy market is sub-segmented into:
By technology segment, the Asia Pacific stem cell therapy market is sub-segmented into:
By application segment, the Asia Pacific stem cell therapy market is sub-segmented into:
By end user segment, the Asia Pacific stem cell therapy market is sub-segmented into:
By country, the Asia Pacific stem cell therapy market is sub-segmented into:
Autologous stem cell therapy, and allogeneic stem cell therapy are the two main types of therapies under the stem-cell therapy market that are expected to grow substantially in the future.
Major applications where stem-cell therapies are being used includes musculoskeletal disorders, wounds and injuries, acute graft-versus-host disease (AGVHD), surgeries, gastrointestinal diseases, cardiovascular diseases, inflammatory & autoimmune diseases, neurological disorders, and others.
The main benefits of stem-cell therapy include the treatment of cardiovascular diseases, helps in healing the incisions and wounds, progress in the treatment of neurogenerative diseases, autoimmune diseases, and in orthopaedic conditions as well, etc.
Stem cell therapies have gained a lot of popularity in recent years, as people look for the most cutting-edge alternative treatments for their various conditions. Through interdisciplinary & multidisciplinary research, clinical applications of engineered stem cells, transplantation, and the development of gene therapy, transplantation, the stem cell technology is advancing significantly. Stem cell research frequently makes use of technologies like stem cell culture, separation, and identification methods. Moreover, in recent years, experimental methods for stem cell isolation and culture have undergone significant development.
The Asia Pacific stem-cell therapy market is projected to grow at a CAGR of 10.29% during the forecast period 2023-2031 and is expected to reach US$ 3,420.05 million by 2031.
Factor such as spurred demand for regenerative medicines, and funds availability for stem cell research drives the growth in the Asia Pacific stem-cell therapy market over the forecast period.
Allogeneic stem cell therapy segment holds the largest CAGR in the Asia Pacific stem-cell therapy market during the forecast period.
Problems associated with embryonic stem cells from an ethical standpoint inhibits the growth of the stem-cell therapy market during the forecast period, 2023-2031.
China holds the major share in term of revenue in the Asia Pacific stem-cell therapy market.
Growing launches of novel products provides a lucrative growth opportunity in the Asia Pacific stem-cell therapy market.
Therapy Type, Product, Cell Source, Technology, Application, End User, and Country are different segments in the Asia Pacific stem-cell therapy market.
Brainstorm Cell Limited, AlloSource, Anterogen Co. Ltd., and Astellas Pharma Inc, among others are the major key players in the Asia Pacific stem-cell therapy market.